Panaxium is developing implantable iontronic neurostimulation technology for personalized stroke and brain-injury recovery. The company sits within implantable neuromodulation and bioelectronic medicine, with a focus on restoring impaired motor, speech, and cognitive function after neurological injury.

Its platform combines soft iontronic brain-surface interfaces, AI-enabled neuroimaging, and adaptive stimulation protocols tailored to each patient’s anatomy and injury profile. The implant is designed to conform to neural tissue, record activity, stimulate target circuits, and support signal-informed therapy optimization over time.

Panaxium initially targets stroke recovery, with broader relevance to brain injury and neurorehabilitation. The company is best understood as a clinical-stage neuromodulation developer applying sensing and stimulation concepts from BCI to restorative therapy.